title: Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
abstract: An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the capacity of bnAbs to neutralize HIV-1 prior to and post-CD4 engagement and to block HIV-1 cell-cell transmission. Cell-cell spread is known to promote a highly efficient infection with HIV-1 which can inflict dramatic losses in neutralization potency compared to free virus infection. Selection of bnAbs that are capable of suppressing HIV irrespective of the transmission mode therefore needs to be considered to ascertain their in vivo activity in therapeutic use and vaccines. Employing assay systems that allow for unambiguous discrimination between free virus and cell-cell transmission to T cells, we probed a panel of 16 bnAbs for their activity against 11 viruses from subtypes A, B and C during both transmission modes. Over a wide range of bnAb-virus combinations tested, inhibitory activity against HIV-1 cell-cell transmission was strongly decreased compared to free virus transmission. Activity loss varied considerably between virus strains and was inversely associated with neutralization of free virus spread for V1V2- and V3-directed bnAbs. In rare bnAb-virus combinations, inhibition for both transmission modes was comparable but no bnAb potently blocked cell-cell transmission across all probed virus strains. Mathematical analysis indicated an increased probability of bnAb resistance mutations to arise in cell-cell rather than free virus spread, further highlighting the need to block this pathway. Importantly, the capacity to efficiently neutralize prior to CD4 engagement correlated with the inhibition efficacy against free virus but not cell-cell transmitted virus. Pre-CD4 attachment activity proved strongest amongst CD4bs bnAbs and varied substantially for V3 and V1V2 loop bnAbs in a strain-dependent manner. In summary, bnAb activity against divergent viruses varied depending on the transmission mode and differed depending on the window of action during the entry process, underscoring that powerful combinations of bnAbs are needed for in vivo application.
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Lucia
authors.initials: L
authors.lastname: Reh
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Carsten
authors.initials: C
authors.lastname: Magnus
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Merle
authors.initials: M
authors.lastname: Schanz
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Weber
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Therese
authors.initials: T
authors.lastname: Uhr
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Peter
authors.initials: P
authors.lastname: Rusert
authors.affiliation: Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Trkola
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology*
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies